3.5. Safety and Adverse Effects
scotoma
CHOROIDAL NEOVASCULARIZATION, ADVERSE EFFECTS, CORNEA
None of the participants showed HCQ toxicity manifested by cornea verticillata or changes in the red-to-white macular field of vision. Perimetric follow-up was performed by using the MP1 OCT and showed that none of the participants developed absolute or relative scotoma, and MP1 general-reduction-of-light threshold was not detected in any of the participants of the study group nor in the control group during the two-year follow-up.None of the participants in the study group developed GA or active choroidal neovascularization. None of the participants in the control group developed active AMD; however, one participant developed GA in both eyes. The trial ended, as planned, two years after commencement. None of the trial participants had any systemic adverse effects.